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Glutamine dependence is a unique metabolic defect seen in cutaneous melanoma (CM), 
directly influencing the prognosis and treatment. Here, we investigated the associations between 
6,025 common single-nucleotide polymorphisms (SNPs) in 77 glutamine metabolic pathway 
genes with CM-specific survival (CMSS) using two published genome-wide association study 
(GWAS) datasets. In the single-locus analysis, 76 SNPs were significantly associated with CMSS 
(P < 0.050, false-positive report probability < 0.2 and Bayesian false discovery probability < 0.8) 
in the discovery dataset, of which seven SNPs were replicated in the validation dataset and three 
SNPs (HAL rs17676826T>C, LGSN rs12663017T>A and NOXRED1 rs8012548A>G) 
independently predicted CMSS, with an effect-allele attributed adjusted hazards ratio of 1.52 (95% 
confidence interval=1.19-1.93) and P<0.001, 0.68 (0.54-0.87) and P=0.002 and 0.62 (0.46-0.83) 
and P=0.002, respectively. The model including the number unfavorable genotypes (NUGs) of 
these three SNPs and clinical variables improved the five-year CMSS prediction (P = 0.012). 
Further expression quantitative trait loci (eQTL) analysis found that the LGSN rs12663017 A 
allele was significantly associated with increased mRNA expression levels (P = 8.89×10
-11
) in 
lymphoblastoid cell lines of the 1000 Genomes Project database; In the analysis of the genotype 
tissue expression (GTEx) project datasets, HAL rs17676826 C allele and NOXRED1 rs8012548 
G allele were significantly associated with their mRNA expression levels in sun-exposed skin of 




, respectively) and in sun-not-exposed suprapubic skin 
(P < 0.001 and 1.43×10
-8
, respectively). Taken together, these genetic variants of 




Cutaneous melanoma (CM) is the most aggressive and treatment-resistant form of skin 
cancers (1). According to American Cancer Society, CM mortality remains high and stable in the 
past two decades, while dramatic declining trends are observed in most of other cancers (2, 3). 
Therefore, it is imperative to further identify the factors that predispose patients to poor survival 
outcome and to improve rationally prediction of prognosis and management of personalized 
treatment for CM patients. 
Initiated by Warburg’s seminal work, discoveries in metabolic alterations in cancer continue 
to raise tremendous interest (4-7). Glutamine dependency, the abnormally increased 
glutaminolysis, has been widely recognized as an important hallmark of cancer metabolism (5, 
7-10). Glutamine, the most abundant free amino acid, plays a key role in cancer progression, 
including maintenance of carboxylic acid pools in the tricarboxylic acid cycle, sustaining cellular 
oxidative phosphorylation, and synthesis of the nonessential amino acids, purine, pyrimidines 
and fatty acids (9-11). To meet the dramatically increasing demand of glutamine in cancer, 
glutamine metabolism-related enzymes and transporters are overwhelmingly induced by 
oncogenes (7, 10, 12), and agents targeting glutamine metabolism including glutamine-mimetic 
compounds, inhibitors to glutaminase (GLS) or glutamate dehydrogenase (GDH) are proved to 
be effective in inhibiting cancer progression (10, 11, 13). Recently, glutamine addiction has also 
been identified in CM (1, 14, 15). Unlike glutamine-independence in melanocytes, melanoma 
cells, irrespective of their genetic backgrounds [e.g., mutated B-Raf Proto-Oncogene (BRAF), 
NRAS Proto-Oncogene (NRAS), or p53], all depend on glutamine for growth (1, 15-17), 
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consuming up to seven-fold more glutamine than melanocytes (15, 17, 18), whereby glutamine 
specifically provides a strong anaplerotic input, contributing to the biosynthesis of fatty acid and 
proline in hypoxia. In light of the glutamine’s essential role in CM, it is important to 
comprehensively understand the regulation of glutamine metabolism in CM patients. 
Multiple genetic alterations, either germline or somatic, have been reported to be involved in 
oncogenic transformation and progression of CM (19),(20, 21). Glutamine dependence in cancer 
may be due to one or a combination of deletions, polymorphisms or alterations in the genes of the 
glutamine/glutamine family amino acid metabolic process and glutamine transporters. Few 
studies have investigated the roles of genetic variants of the glutamine pathway genes in 
prognosis of melanoma. One study found that genetic variants of the glutamine transporter 
SLC1A5 (ASCT2) were associated with prognosis of hepatocelluar carcinoma patients (22). In 
the present study, we aimed to determine whether common genetic variants involved in the 
glutamine metabolism process are associated with CM-specific survival (CMSS) using two 
published genome-wide association study (GWAS) datasets, which may help identify promising 
prognostic biomarkers and support scientific foundation on the possible metabolism-based 
therapeutics.  
 
Materials and Methods 
Study populations and genotyping data 
Two GWAS datasets were used in the present study: the discovery dataset and the validation 
dataset. The discovery dataset was from The University of Texas MD Anderson Cancer Center 
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(MDACC) and the validation dataset was from the Nurses’ Health study (NHS) and the Health 
Professionals Follow-up Study (HPFS) conducted by Harvard Brigham and Women’s Hospital. 
The study protocols were approved by Institutional Review Boards at both MDACC and Harvard 
Brigham and Women’s Hospital with a written consent from each of the subjects. 
In the MDACC GWAS study, 858 non-Hispanic white patients diagnosed with histologically 
confirmed CM were accrued for a hospital-based case-control study between March 1998 and 
August 2008. The complete information (19, 21) for demographic and prospective 
clinicopathological data of the patients were obtained from a standard life-style questionnaire 
and/or extracted from patient medical charts. The genotypes were called by using the 
BeadStudio algorithm at John Hopkins University Center for Inherited Disease Research. 
Genome-wide imputation was conducted with the MACH software based on the 1000 Genomes 
Project, phase 1 v2 CEU data (23). SNPs with a minor allele frequency (MAF) ≥ 0.05, a 
genotyping rate ≥ 95%, and Hardy-Weinberg equilibrium P values ≥ 1×10-5 were included in the 
final analysis. The MDACC dataset can be accessed at the Database of Genotypes and 
Phenotypes (dbGaP: http://www.ncbi.nlm.nih.gov/gap) with an accession number 
phs000187.v1.p1 (24). The detailed genotyping information and data quality control have been 
reported (19, 25). 
In the Harvard NHS/HPFS GWAS study, the two cohorts of NHS and HPFS were established 
in 1976 and 1986, respectively (26). In the NHS, the information on CM development was first 
collected in 1984 and 90% of participants had completed health-related information for >20 years. 
In the HPFS, the related information was first collected in 1984 and the average follow-up rate 
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over 10 years was>90%. Eligible subjects in both cohorts were participants with 
histopathologically confirmed invasive melanoma, diagnosed at any time after baseline up to the 
2008 follow-up cycle. All subjects were non-Hispanic whites in the United States. In the final 
analysis, 409 patients were included in the data after quality control. Genotyping was performed 
using the Illumina HumanHap610 array. Genome-Wide imputation was also performed using the 
MACH program based on the 1000 Genomes Project (Utah Residents with Northern and Western 
European Ancestry data, phase I v3) (27, 28). SNPs with imputation quality r2≥ 0.8 and MAF≥ 
0.05 were included in the final analysis. 
 
Gene and SNP selection 
Based on the database of the Molecular Signatures Databases and literatures (13, 29, 30), 
84 autosome genes of the glutamine/glutamine family amino acid metabolic process and 
glutamine transporters were selected to further investigation (Supporting information Table 1). 
After excluding seven genes in the X chromosome, SNPs within the remaining 77 genes and their 
2-kb flanking regions were extracted from the MDACC GWAS dataset. 
 
In silico functional analysis as a biological validation 
For those validated SNPs as significant ones, bioinformatics functional prediction was 
performed firstly by using two online tools: RegulomeDB (http://www.regulomedb.org) and 
HaploReg (http://archive.broadinstitute.org/mammals/haploreg/haploreg.php) (31, 32). Then, the 
expression quantitation trait loci (eQTL) analysis was conducted by using data from multiple 
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sources: lymphoblastoid cell data of 373 European individuals from Genetic European Variation 
in Health and Disease Consortium (GEUVADIS) and the 1000 Genomes Project (phase I 
integrated release 3, March 2012) (27); the whole blood, skin or the subcutaneous adipose tissue 
data from the genotype tissue expression (GTEx) project (33); tumor and adjacent normal tissue 
data from the Cancer Genome Atlas (TCGA) database (34).  
 
Statistical methods 
CMSS was defined as the primary endpoint of the present study, for which survival time 
started at the date of diagnosis of CM and ended at the date of CM-related death or the last 
follow-up. Deaths with non-CM causes were considered censored. The associations between 
SNPs and CMSS (in an additive genetic model) were analyzed by both univariable and 
multivariable Cox proportional hazards regression models using the GenABEL package of R 
software, with adjustment for age, sex, Breslow thickness, tumor stage, tumor cell mitotic rate 
and ulceration of tumor in the MDACC GWAS dataset and for age and sex in the Harvard 
NHS/HPFS GWAS dataset. Bayesian measure of the false-positive report probability (FPRP) (35) 
correction was applied to limit the probability of false-positive findings as a relatively large number 
SNPs had been tested. We chose the less stringent FPRP for multiple test correction, because 
the vast majority (5089 out of 6209) of the SNPs included in the analysis were imputed with a 
high LD with the 1124 genotyped SNP (Fig. 1A). Only those SNPs with an FPRP value < 0.2 
were considered worthy of subsequent validation in the Harvard NHS/HPFS GWAS dataset. We 
also used false discovery rate (FDR) and another Bayesian measure (BFDP: Bayesian false 
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discovery probability with a cutoff value of 0.8 for identifying noteworthy associations, which 
refines the criteria for FPRP) for identifying noteworthy associations (36). Linkage disequilibrium 
(LD) analysis was performed by using HaploView 4.2 according to European populations from the 
1000 Genome Project with pairwise r2=0.8 as a cut-off value.  
The stepwise Cox regression model including validated SNPs and clinical variables was 
performed to choose the independent SNPs. Meta-analysis was conducted using PLINK 1.09. 
Cochran’s Q statistics and I2 were carried out to access an inter-study heterogeneity. 
Fixed-effects models were used when no heterogeneity was found between two studies (Q test P 
values >0.1. and I2< 25.0%); otherwise, random-effects models were used. The number of 
unfavorable (risk) or protective genotypes (NUGs) was used as a genetic risk (protective) score 
to assess the combined effect of all independent and significant SNPs. Manhattan plot and 
quantile-quantile plot were performed using qqman package of R software. Kaplan-Meier survival 
curves and Log-rank tests were performed to visually evaluate the effects of NUGs on CMSS. 
The receiver operating characteristic (ROC) curve and time-dependent area under the curve 
(AUC) were constructed from the logistic regression model with the survival ROC package of R 
software. Statistical significance of the improvement in AUC was analyzed by the Delong’s test. 
All analyses were performed using SAS (version 9.1.4; SAS Institute, Cary, NC), unless 
otherwise specified. Fig. 1A provides the study follow chart, illustrating procedures of analyses 





Basic characteristics of the two GWAS datasets 
The analysis included 858 patients from the MDACC GWAS dataset and 409 patients from the 
Harvard NHS/HPFS GWAS datasets, and basic characteristics of these subjects had been 
previously described (21) (Supporting information Table 2). In the MDACC GWAS dataset, the 
age of patients ranged between17 and 94 years at diagnosis (52.4 ± 14.4 years), and there were 
more men (496, 57.8%) than women (362, 42.2%). Meanwhile, more patients had a stage I/II 
disease (709, 82.6%) than a stage III/IV disease (149, 17.4%), with a median follow-up time of 
81.1 months, during which 95 (11.1%) patients died of CM. In addition, univariable Cox 
regression analysis indicated that age, sex, regional/distant metastasis, Breslow thickness, 
ulceration, and mitotic rate were significantly associated with CMSS. In the NHS/HPFS GWAS 
dataset, the age of the included patients was between 34 and 87 years at diagnosis (61.1 ± 10.8 
years), and 66.3% (271) of the patients were women. Compared with that of the MDACC patients, 
the median follow-up time of the patients was relatively longer (179.0 months), during which 48 
(11.5%) patients died of CM, and only age was significantly associated with CMSS in univariable 
Cox regression analysis of the NHS/HPFS GWAS dataset, because other clinicopathologial 
variables were not available.  
 
SNPs and CMSS 
In the discovery MDACC GWAS dataset, Cox regression analysis was firstly performed to 
assess associations of a total of 6,209 common SNPs of the glutamine metabolism-related 
pathway genes with CMSS. Manhattan plot of associations between these variants and CMSS in 
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MDACC dataset is shown in Fig. 1B. The quantile-quantile plot of the observed P values showed 
a uniform distribution (Fig. 1C). In a single locus analysis, 252 SNPs were found to be 
significantly associated with CMSS at P < 0.05 in an additive genetic model, of which 76 SNPs 
were still considered noteworthy after the correction by the FPRP < 0.2 and BFDP < 0.8. Then, 
these 76 SNPs were further subjected to validation in the Harvard NHS/HPFS GWAS dataset. As 
shown in Table 1, seven SNPs in three genes identified in the discovery phase remained 
statistically significant (P < 0.05), of which rs17676826 in histidine ammonia-lyase ( HAL) was 
significantly associated with a poorer survival, while the other five SNPs of Lengsin ( LGSN) and 
rs8012548 in NADP-dependent oxidoreducatase domain-containing protein 1 (NOXRED1) were 
associated with a better survival in both datasets. Additionally, the noteworthy associations were 
also assessed by FDR (Supporting information Table 3). Subsequent meta-analysis of these 
SNPs from both datasets showed that these associations remained statistically significant, and 
there was no evidence for heterogeneity in these seven SNPs between the two GWAS datasets. 
 
Three independent SNPs as CM survival predictors 
We further performed functional prediction with RegulomeDB and HaploReg30 for these 
validated SNPs (Supporting information Table 4). As indicated by RegulomeDB, the score of 
HAL rs17676826 was 4, and functional annotation of this SNP in HaploReg demonstrated that it 
overlaps with an enhancer, potentially disrupting four motifs [i.e., Zinc finger and BTB 
domain-containing protein 3 (Zbtb3)] and affecting the mRNA expression. As for the five SNPs in 
LGSN, LD analysis showed that they were in high LD (r2>0.8) (Fig. 1D), of which LGSN 
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rs12663017 may disrupt eight motifs [i.e., Forkhead Box A (FOXA), Histone Deacetylase 2 
(HDAC2), and E1A Binding Protein P300 (EP300)] and affecting mRNA expression of the 
corresponding gene. Additionally, LGSN rs12663017 is located very close to the 3'-UTR 
(untranslated region, 247 bp at the 3’ of LGSN), whereas SNPs rs2253428 and rs2253430 in 
complete LD (r2=1) with the lead variant rs12663017 were located at 3'-UTR. According to the 
HaploReg, NOXRED1 rs8012548 may disrupt the motif of paired like homeodomain 2 (Pitx_2) 
and spermatogenic leucine zipper 1 (Spz1), affecting the mRNA expression. Moreover, two highly 
linked SNPs with NOXRED1 rs8012548 [i.e., transmembrane emp24 domain-containing protein 8 
(TMED8) rs10141317, r2 = 0.93; TMED8 rs3742737, r2 = 0.94] were identified as missense 
variants. The above-mentioned online functional predictions suggested that these SNPs were 
biologically functional. 
Comprehensively considering the predicted functions, P values and LD, we selected three 
SNPs of HAL rs17676826, LGSN rs12663017 and NOXRED1 rs8012548 as the tagSNPs. Then 
we used initial stepwise Cox regression analyses to identify whether these three SNPs were 
independent predictors of CMSS. The results suggested that these three tagSNPs were 
statistically significant independent predictors of CMSS (Table 2).  
For each of the three independent SNPs, univariable and multivariable Cox regression 
analysis were further performed to evaluate their effects on death risk with adjustment of other 
clinicopathological covariates (Table 3). In the MDACC dataset, risk of death was significantly 
increased with the number of HAL rs17676826 C allele (Ptrend = 0.001) but was significantly 
decreased with the number of LGSN rs12663017 A and NOXRED1 rs8012548 G alleles (Ptrend = 
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0.024 and 0.021, respectively). Similarly, consistent trends were observed in the Harvard 
NHS/HPFS dataset (Ptrend = 0.029, 0.025 and 0.030, respectively) and in the MDACC and 
NHS/HPFS combined dataset (Ptrend = 0.029, 0.004 and 0.030, respectively). In addition, regional 
association plots for variants in HAL, LGSN and NOXRED1, including the 50-kb regions flanking 
the neighborhoods of these genes, are shown in Supporting information Fig. 1. 
 
Combined effects of the three independent SNPs 
To better evaluate the joint effect of the three independent SNPs on risk of death, the risk 
genotypes (i.e., HAL rs17676826 TC+CC, LGSN rs12663017 TT and NOXRED1 rs8012548 AA) 
were combined into one variable as a genetic score as the number of unfavorable genotypes 
(NUGs) (Table 3). The trend test indicated that an increased number of NUGs was associated 
with an increased risk of death in the MDACC (P < 0.001), NHS/HPFS (P = 0.010) and the 
combined (P = 0.012) datasets. We further divided the combined NUGs into a low-risk group (0-1 
NUGs) and a high-risk group (2-3 NUGs) and found that the HR for the high-risk group was 2.04 
fold (CI =1.32-3.15, P = 0.001), 1.66 fold (CI= 0.94-2.92, P = 0.082) and 1.90 fold (CI= 1.37-2.66, 
P < 0.001) for the MDACC, NHS/HPFS and the combined datasets, respectively, compared with 
the low-risk group. For the illustrative purpose, Kaplan-Meier survival curves of these 
associations of the NUGs with CMSS are depicted in Figs. 2A-2B and Supporting information 
Fig. 2. 
 
Stratified analyses for associations between NUGs and CMSS 
 
 14 
Additional stratified analysis was carried out to investigate whether the combined effect of 
unfavorable genotypes on CMSS was modified by clinical variables in the MDACC dataset. 
Compared with those with 0-1 NUGs, individuals with 2-3 NUGs showed a poorer survival in the 
presence of clinicopathologic risk factors in the stratified subgroups of > 50 years old, male, 
female, with regional/distant metastasis, Breslow’s thickness > 1mm, ulceration and mitotic rate > 
1mm2, and no heterogeneity was observed among these subgroups (Supporting information 
Table 4).  
 
The ROC curve and time dependent AUC 
We further estimated predictive value of the NUGs with time-dependent AUC and ROC 
curves using the combined MDACC and NHS/PFS datasets. As shown in Fig. 2C, the 
time-dependent AUC plot indicated an improved prediction performance with the addition of 
NUGs to the model with clinicopathologic risk factors (age and sex) from the beginning of the 
follow-up and remaining over time, compared with clinicopathologic factors only. As for 
classification of five-year CMSS (Fig. 2D), the AUCs were increased from 61.25% to 67.34% (P = 
0.012), which were statistically significant after adding NUGs into the model with clinicopathologic 
risk factors.  
 
The eQTL analysis using 1000 Genomes Project database 
To evaluate correlations between SNPs and their corresponding mRNA expression levels, 
we primarily used the RNA-Seq data of lymphoblastoid cell lines from 373 European 
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descendants included in the database of the 1000 Genomes Project. As shown in Figs. 3A, 
LGSN rs12663017 TA and AA genotypes (or the A allele) were significantly associated with 
increased mRNA expression levels of LGSN (trend test in an additive model: P = 8.89 × 10
-11
), 
but this trend was not observed for HAL rs17676826 (P = 0.341) and NOXRED1 rs8012548 (P = 
0.079).  
 
The eQTL analysis using the GTEx project database 
Then, we further conducted the eQTL analysis using data from the GTEx. In skin tissues 
from the donors, the HAL rs17676826C allele was associated with a significant increase in mRNA 
expression levels in sun-exposed skin of the lower leg (P = 6.62×10
-6
, Fig. 3B-a) and in 
sun-not-exposed suprapubic skin (P = 0.0011, Fig. 3B-b); the NOXRED1 rs8012548 G allele was 
associated with a significant decrease in mRNA expression levels in sun-exposed skin of the 
lower leg (P = 1.37×10
-7
, Fig. 3B-c) and sun-not-exposed suprapubic skin (P = 1.43×10-8, Fig. 
3B-d), and the two highly-linked variants (i.e., rs10141317 and rs10141317) were also 
associated with a significant decrease in NOXRED1 mRNA expression levels in sun-exposed 
skin of the lower leg (rs10141317 T allele, P = 4.10 ×10
-7
and rs3742737 T allele, P = 3.10 ×10
-7
) 
and sun-not-exposed suprapubic skin (rs10141317 T allele, P = 1.60 ×10
-8
and rs3742737 T allele, 
P = 1.10 ×10
-8
); whereas there was no data about LGSN rs12663017 in skin tissues.  
Additionally, according to the GTEx portal, LGSN the rs12663017A allele was associated 
with a significant increase in mRNA expression levels (P = 3.90×10
-9
, Fig. 3B-e) in the whole 
blood from the donors, and the same trends were observed in its six highly-linked variants (data 
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not shown); the NOXRED1 rs8012548G allele was associated with a significant decrease in 
mRNA expression levels in subcutaneous adipose tissue (P = 2.20×10
-5
, Fig. 3B-f) from the 
donors. 
 
The eQTL analysis using the TCGA database 
We also performed SNPs and mRNA expression correlation analysis by using the expression 
data in tumor tissues from 473 cases of CM from the TCGA database; however, there was no 
significant association between HAL rs17676826 and its mRNA expression levels (P = 0.412 in 
additive model); the other two tag SNPs were not included in the TCGA dataset.  
Furthermore, associations between mRNA expression and lung cancer overall survival in 
TCGA database were investigated by using OncoLnc (http://www.oncolnc.org/). According to 
OncoLnc, CM patients with higher NOXRED1 mRNA expression levels in tumor tissue showed a 
better overall survival (P = 0.025) in TCGA database; Kaplan-Meier survival curves for 
NOXRED1 in CM with the bottom quartile vs. top quartile of NOXRED1 mRNA expression levels 
were shown in Fig. 3C. However, no significant associations were found between the HAL or 
LGSN mRNA expression and CM overall survival in TCGA database by using OncoLnc. 
 
Discussion 
To our knowledge, this is the first report about the associations between genetic variants in 
the glutamine metabolism pathway genes and CMSS. Using publically available genotyping data 
from two published GWAS datasets, we revealed that genetic variants of HAL rs17676826, LGSN 
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rs12663017 and NOXRED1 rs8012548 either individually or jointly modulated the survival of 
patients with CM. Remarkably, the effect was consistent across analyses of different datasets 
and through stratified analyses, and the genotype-survival association was pronounced even in 
the presence of clinicopathological risk factors, such as Breslow thickness and mitotic rate. 
Moreover, these genetic variants were found to influence their mRNA expression levels. These 
findings suggest that genetic variants in the glutamine metabolism pathway genes may have 
biological roles in CM progression, possibly through a mechanism of modulating expression of 
these genes, which would provide new scientific insights into metabolism-based therapeutics for 
cancer. 
HAL, located on chromosome 12q23.1, encodes the histidine ammonia-lyase. Histidine is 
one of the glutamine family amino acids, which are disposed of through conversion to glutamate 
(37). HAL, mainly existing in the epidermis and liver, catabolizes histidine to trans-urocanic acid 
(UCA), an ultraviolet (UV) radiation-absorbing molecule in the stratum corneum, which can be 
photoisomerized to cis-UCA, when exposed to UV, especially UV-B (38-40). Moreover, cis-UCA 
mimics the effects of UV-B-mediated immuno-suppression, which has been recognized as an 
important factor related to skin cancer development (38-40). In the present study, we found that 
rs17676826, located in the intron region of HAL, was associated with a poorer survival in CM 
patients. The rs17676826 position overlaps with an enhancer activity cluster, which is classified 
as a genic enhancer by the 15-state core model and as a transcribed 3' enhancer by the 25-state 
model, according to the Haploreg database (32). Furthermore, histone modification markers 
H3K4me1, H3K4me4 and H3K27ac are all contributing to the chromatin state assignment at this 
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SNP location. Therefore, rs17676826 probably affects gene expression levels by modifying the 
accessibility of chromatin during the transcription. Consistent with that, the rs17676826 C allele 
was found to be associated with a significant increase in mRNA expression levels of HAL in the 
sun-exposed lower leg skin and sun-not-exposed suprapubic skin. Additional Haploreg data show 
that this SNP changes the match to some regulatory motifs, such as Zbtb3, which play important 
roles in cancer cell growth via gene expression of detoxification enzymes for reactive oxygen 
species (41). Overall, these provide a possible explanation to the mechanism underlying the 
observed association between rs17676826 and CMSS.  
LGSN, located on chromosome 6q12, encodes a glutamine synthetase I family protein called 
lengsin that was previously reported to be a constitutive lens-specific protein but without the 
glutaminase activity (42). Recently, lengsin was identified as a novel tumor-associated antigen 
and revealed its essential role in cell survival (42, 43). In the present study, we found that CM 
patients with genotypes of LGSN rs12663017 TA+AA had a better CMSS. This SNP and its 
highly-linked SNPs, rs2253428 and rs2253430, are located very close to or within the 3’-UTR of 
the gene, which indicates that these SNPs may influence the fate of LGSN mRNA and thus 
proteosynthesis. Consistent with that, we found the LGSN rs12663017A allele was associated 
with a significant increase in mRNA expression levels of LGSN in whole blood and 
lymphobplastoid cell lines. Additionally, as indicated in the Haploreg database (32), rs12663017 
can disrupt some important transcription regulators, including FOXA, EP300 and HDAC2, which 
suggests that this SNP is also likely affect gene expression by modifying the remodeling of 
chromatin during transcription. 
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NOXRED1, located on chromosome 6q12, encodes the NADP-dependent oxidoreducatase 
domain-containing protein 1, formerly named C14orf148. According to the Go annotation 
(http://www.geneontology.org/), NOXRED1 is a probable oxidoreductase and belongs to the 
pyrroline-5-carboxylate reductase-like protein (PYCR) family (44). In general, glutamine is 
degraded to glutamate, which then can consecutively be converted to proline by PYCR. Many 
studies have proved that proline is essential for cancer cell growth and that the elevated proline 
pool may enhance production of collagen and new extracellular matrix deposition, facilitating 
tumor invasion (18, 45-47). In the present study, our findings revealed that carriers of the 
NOXRED1 rs8012548 G variant genotypes had a better CMSS. According to the annotation of 
HaploReg (32), the NOXRED1 rs8012548G allele might have some effects on regulatory motifs, 
including Pitx2 and Spz1, which were associated with tumor progression in procollagen lysyl 
hydroxylase translation (48) and toll-like receptor (TLR) activation (49), respectively. Additionally, 
it should be noted that the association between rs8012548 and CMSS could have been 
correlated with the other two highly-linked missense variants (rs10141317 and rs3742737) in 
TMED8. These two TMED8 variants may have substantial functions as they are located at the 
promoter enhancer and DNase I hypersensitive sites, likely to disrupt many motifs in various cells 
and tissues. Consistently, we found that the rs8012548 G allele, the rs10141317 T and 
rs3742737 T alleles were involved in transcriptional regulation as evidenced by eQTL analysis 
from the 1000 Genomes and GTEx projects. Notably, we found that these three SNPs were 
associated with significant decrease in mRNA expression levels in sun-exposed or 
sun-not-exposed skin, which supports an oncogenic effect of NOXRED1. However, in the TCGA 
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database, CM patients with higher NOXRED1 mRNA expression levels in tumor tissue showed a 
better survival. These contradictions might be attributed to many factors including the limited 
samples of the two databases. Therefore, further functional investigation of NOXRED1 are 
needed, especially for the experimental work. 
There were some limitations in the present study. Firstly, there was no available information 
about glutamine or nutritional status, nutrition-based treatment and systemic therapies received 
by the patients. Secondly, although we adjusted in the models for variables (age, sex, Breslow 
thickness, regional/distant metastasis, ulceration, and mitotic rate) that could confound our 
observations of a genetic effect on CMSS for the discovery in the MDACC analysis, only age and 
sex were adjusted in the validation in the Harvard NHS/HPFS dataset. However, no 
heterogeneity was observed, when the two datasets were combined, which indicates that the 
observed effect of each SNP on CMSS from the two studies was consistent. Lastly, no direct 
biological experiments were conducted for functional validations. Further functional studies are 
warranted to investigate the exact function of these SNPs or genes on melanoma progression.  
Because we did not use the FDR as the multiple test correction, it is possible that our findings 
could be of false discovery, and thus additional validation is warranted. Also, additional larger 
validation studies with multiethnic groups are also needed to confirm our results, because our 
prognosis-predicting model was based on a non-Hispanic white patient population. 
In conclusion, the present study identified the roles of genetic variants in HAL (rs17676826), 
LGSN (rs12663017) and NOXRED1 (rs8012548) in CMSS as assessed in two independent 
GWAS datasets. Given the importance of glutamine metabolic alteration in the progression of 
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cancer cells, these genetic variants may represent promising prognostic biomarkers and potential 
subtype classification indicators for personalized metabolic therapies.  
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Figure 1. Screening for independent functional SNPs in the glutamine metabolic pathway 
genes to predict CMSS. (A) Study flowchart; (B) Manhattan plot and (C) quantile-quantile plot 
of associations between variants of the glutamine metabolic pathway and CMSS in MDACC 
dataset. There are 252 SNPs with P < 0.05 and 76 SNPs with FPRP< 0.2 and BFDP < 0.8 in 
the total 6, 209 SNPs of glutamine metabolic pathway. The blue horizontal line indicates P = 
0.05. The red horizontal line indicates FPRP = 0.2 and BFDP = 0.8. (D) LD plots of validated 
five SNPs in LGSN. CMSS, cutaneous melanoma-specific survival; MDACC, The University 
of Texas MD Anderson Cancer Center; SNP, single-nucleotide polymorphism; BFDP, 
bayesian false discovery probability; GWAS, genome-wide association study; HWE, hardy 
Weinberg equilibrium; MAF, minor allele frequency; LD, linkage disequilibrium. 
Figure 2. The combined risk genotypes and survival prediction. Kaplan-Meier survival curves 
of the combined risk genotypes in the MDACC + NHS/HPFS datasets (A), and dichotomized 
groups of the NUG in the MDACC + NHS/HPFS datasets (B); ROC curves and AUC 
estimation for prediction of melanoma-specific survival using the MDACC + NHS/HPFS 
datasets, (C) Time-dependent AUC estimation, based on age, sex and the risk genotypes of 
the three independent genes, and (D) Five-year melanoma-specific survival ROC curves (P = 
0.012). NUG, number of unfavorable genotypes; MDACC, The University of Texas MD 
Anderson Cancer Center. ROC, Receiver operating characteristic; AUC, Time-dependent 
area under the ROC curve.  
Figure 3. Associations between the risk genotypes and their corresponding mRNA 
expression levels. (A) The eQTL in 373 Europeans from the 1000 Genomes Project for (a) 
HAL rs17676826, (b) LGSN rs12663017 and (c) NOXRED1 rs8012548 in the additive model; 
(B) the eQTL from the GTEx project using the additive model for HAL rs17676826 in skin 
tissues from sun-exposed lower leg skin (a) and sun-not-exposed suprapubic (b), NOXRED1 
rs8012548 in skin tissues from sun-exposed lower leg (c) and sun-not-exposed suprapubic 
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(d), LGSN rs12663017 in the whole blood (e), and NOXRED1 rs8012548 in subcutaneous 
adipose (e). (C) Kaplan-Meier survival plot for NOXRED1 in CM patients from TCGA 
database. Survival analyses based on different mRNA expression levels of NOXRED1 in the 
bottom quartile vs. top quartile in 458 CM patients of European descents from TCGA 
database, which were analyzed by OncoLnc (http://www.oncolnc.org). eQTL, expression 
quantitative trait loci analysis. GTEx, Genotype-Tissue Expression; CM, cutaneous melanoma; 
TCGA, The Cancer Genome Altas. 
1 
 Table 1. Meta-analysis of seven validated SNPs of genes in the glutamine metabolic pathway using two published MDACC and NHS/HPFS melanoma GWAS datasets 
SNP Allele1 Gene Position 





EAF HR (95% CI)2 P2 FPRP BFDP3  EAF HR (95% CI)4 P4  Phet5 I2 HR (95% CI) 6 P6 
rs17676826# T/C HAL 12q23.1 0.31 1.48 (1.1-1.99) 0.010 0.081 0.570  0.28 1.59 (1.05-2.42) 0.029  0.784 0 1.52 (1.19-1.93) 7.46x 10-4 
rs1723518$ G/A LGSN 6q12 0.45 0.71 (0.53-0.95) 0.022 0.165 0.292  0.48 0.63 (0.41-0.94) 0.025  0.645 0 0.68 (0.54-0.87) 1.80 x 10-3 
rs9341780$ G/T LGSN 6q12 0.45 0.71 (0.53-0.95) 0.022 0.165 0.292  0.48 0.63 (0.41-0.94) 0.025  0.644 0 0.68 (0.54-0.87) 1.80 x 10-3 
rs1007519$ C/T LGSN 6q12 0.45 0.71 (0.53-0.96) 0.024 0.179 0.212  0.48 0.62 (0.41-0.94) 0.025  0.600 0 0.68 (0.53-0.86) 1.53 x 10-3 
rs1711934$ G/C LGSN 6q12 0.45 0.71 (0.53-0.96) 0.024 0.179 0.253  0.48 0.63 (0.42-0.96) 0.032  0.687 0 0.69 (0.54-0.87) 2.02 x 10-3 
rs12663017$ T/A LGSN 6q12 0.45 0.71 (0.53-0.96) 0.024 0.179 0.738  0.48 0.64 (0.41-0.94) 0.025  0.644 0 0.68 (0.54-0.87) 1.79x 10-3 
rs8012548$ A/G NOXRED1 14q24.3 0.24 0.65 (0.45-0.94) 0.021 0.169 0.713  0.28 0.56 (0.33-0.94) 0.029  0.645 0 0.62 (0.46-0.83) 1.57x 10-3 
Abbreviations: SNP, single nucleotide polymorphism; GWAS, genome-wide association study; MDACC, The University of Texas M.D. Anderson Cancer Center; NHS/HPFS,   Nurses' 
Health Study/Health Professionals Follow-up Study; EAF, effect allele frequency; HR, hazards ratio; CI, confidence interval; FPRP, false-positive report probability; BFDP, Bayesian 
false discovery probability. 
Phet, P value for heterogeneity by Cochrane’s Q test; 
1Reference allele/effect allele; 
2Adjusted for age, sex, Breslow thickness, distant/regional metastasis, ulceration and mitotic rate in additive model; 
3With a prior probability of 0.10 to detect an HR of 2.0 for an association with variant genotypes or minor alleles of the SNPs with P < 0.05. 
4Adjusted for age and sex in additive model; 
5Phet, P value for heterogeneity by Cochrane’s Q test; 
6Meta-analysis in the fix-effect model; 
# Genotyped SNP in the MDACC study; 
$ Imputed SNP in the MDACC study. 
  1 
2 
  2 
Table 2. Independent predictors of CMSS as obtained from the stepwise Cox regression analysis of selected variables from the MDACC dataset 
Parameter1 Category2 Frequency HR (95% CI) P 
Age ≤50/>50 371/487 1.02 (1.01-1.04) 0.049 
Sex Female/Male 362/496 1.45 (0.91-2.32) 0.116 
Regional/distant metastasis No/Yes 709/149 4.48 (2.89-6.96) <.0001 
Breslow thickness(mm) ≤1/>1 347/511 1.15 (1.09-1.21) <.0001 
Ulceration No/Yes 681/155 2.86 (1.86-4.41) <.0001 
Mitotic rate (mm2) ≤1/>1 275/583 2.48 (1.21-5.09) 0.013 
HAL rs17676826 T>C TT/TC/CC 410/361/87 1.46 (1.08-1.97) 0.015 
LGSN rs12663017T>A TT/TA/AA 271/400/187 0.71 (0.52-0.96) 0.025 
NOXRED1 rs8012548 A>G AA/AG/GG 485/327/46 0.67 (0.47-0.97) 0.032 
Abbreviations: CMSS, cutaneous melanoma-specific survival; MDACC, The University of Texas MD Anderson Cancer Center; HR, hazards ratio; CI, confidence interval; 
1 Stepwise analysis included age, sex, regional/distant metastasis, Breslow thickness, ulceration, mitotic rate and three SNPs (rs17676826 in HAL, rs12663017 in LGSN and rs8012548 
in NOXRED1) in three genes. 
2 The “category” was used as the reference. 
3 
 3 
Table 3. Associations between three independent SNPs in the glutamine metabolic pathway genes and CMSS of patients in the MDACC study and NHS/HPFS study 
 MDACC (n=858)  NHS/HPFS (n=409)  MDACC + NHS/HPFS (n=1267)  
Genotype Frequency Multivariate analysis1 
 
Frequency Multivariate analysis2  Frequency Multivariate analysis3 
  All Death (%) HR (95%CI) P   All Death (%) HR (95%CI) P  All Death (%) HR (95%CI) P 
HAL rs17676826 T>C            
TT 410 36 (8.78) 1.00  
 
214 21 (9.81) 1.00   624 57 (9.13) 1.00  
TC 361 50 (13.85) 2.19 (1.39-3.45) <0.001 
 
161 19 (11.80) 1.26 (0.68-2.34) 0.467  522 69 (13.22) 1.60 (1.12-2.27) 0.009 
CC 87 9 (10.34) 1.61 (0.76-3.40) 0.212 
 
34 8 (23.53) 2.93 (1.29-6.64) 0.010  121 17 (14.05) 1.83 (1.06-3.15) 0.030 
Trend test   0.010 
    0.029  
   0.004 
TC+CC 448 59 (13.17) 2.07 (1.34-3.21) 0.001 
 
195 27 (13.85) 1.51 (0.85-2.68) 0.156  643 86 (13.37) 1.64 (1.17-2.29) 0.004 
LGSN rs12663017 T>A           
TT 271 38 (14.02) 1.00  
 
109 16 (14.68) 1.00   380 54 (14.21) 1.00  
TA 400 45 (11.25) 0.88 (0.56-1.37) 0.559 
 
207 28 (13.53) 0.92 (0.50-1.71) 0.803  607 73 (12.03) 0.80 (0.56-1.14) 0.218 
AA 187 12 (6.42) 0.44 (0.22-0.87) 0.018 
 
93 4 (4.30) 0.27 (0.09-0.81) 0.019  280 16 (5.71) 0.36 (0.21-0.64) <0.001 
Trend test   0.024 
    0.025  
   0.0004 
TA+AA 587 57 (9.71) 0.73 (0.48-1.12) 0.153 
 
300 32 (10.67) 0.71 (0.39-1.29) 0.261  887 89 (10.03) 0.66 (0.47-0.92) 0.016 
NOXRED1 rs8012548 A>G           
AA 485 59 (12.16) 1.00  
 
215 32 (14.88) 1.00   700 91 (13.00) 1.00 0.028 
AG 327 34 (10.40) 0.79 (0.51-1.21) 0.274 
 
162 15 (9.26) 0.62 (0.34-1.15) 0.13  489 49 (10.02) 0.78 (0.55-1.10) 0.152 
GG 46 2 (4.35) 0.21 (0.05-0.86) 0.030 
 
32 1 (3.13) 0.20 (0.03-1.46) 0.112  78 3 (3.85) 0.27 (0.09-0.86) 0.027 
Trend test   0.021 
    0.030  
   0.012 
AG+GG 373 36 (9.65) 0.68 (0.45-1.05) 0.081 
 
194 16 (8.25) 0.55 (0.30-1.00) 0.051  567 52 (9.17) 0.70 (0.50-0.99) 0.041 
Number of risk genotypes4           
0 134 9 (6.72) 1.00   80 4 (5.00) 1.00   214 13 (6.07) 1.00  
1 319 27 (8.46) 1.92 (0.89-4.13) 0.097  164 19 (11.59) 2.50 (0.85-7.35) 0.096  483 46 (9.52) 1.64 (0.89-3.04) 0.115 
2 330 48 (14.55) 3.03 (1.47-6.27) 0.003  140 19 (13.57) 2.91 (0.99-8.56) 0.053  470 67 (14.26) 2.62 (1.44-4.74) 0.002 
3 75 11 (14.67) 3.98 (1.59-9.98) 0.003 
 
25 6 (24.00) 5.52 (1.56-19.56) 0.008  100 17 (17.00) 3.39 (1.64-6.99) 0.001 
Trend test 
  <0.001 
    0.010  
   < 0.001 
0-1 453 36 (7.95) 1.00  
 
244 23 (9.43) 1.00   697 59 (8.46) 1.00  
2-3 405 59 (14.57) 2.04 (1.32-3.15) 0.001   165 25 (15.15) 1.66 (0.94-2.92) 0.082  570 84 (14.74) 1.90 (1.37-2.66) <0.001 
Abbreviations: SNP, single nucleotide polymorphisms; CMSS, cutaneous melanoma-specific survival; GWAS, genome-wide association study; MDACC, The University of Texas MD Anderson 
Cancer Center; NHS/HPF, Nurses' Health Study/Health Professionals Follow-up Study; HR, hazards ratio; CI, confidence interval; 
1Adjusted for age, sex, Breslow thickness, distant/regional metastasis, ulceration and mitotic rate in Cox models of SNPs and CMSS in MDACC study;  
2Adjusted for age and sex in NHS/HPFS study; 
3Adjusted for age and sex in MDACC and NHS/HPFS study;          
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(Go; Delete Chr. X/Y) 
6,209 common SNPs 
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Individual call rate > 95%; MAF > 5%; 
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Cox regression multivariate analysis 
252 SNPs significantly associated with CMSS 
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7 SNPs were validated with P < 0.05 
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SNP-Gene expression analysis 
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Supporting information Figure Legends 
Supporting information Figure 1. Regional association plots for three independent 
SNPs in MDACC study. SNPs in the region of 50 kb up or downstream of HAL 
rs17676826 (A), LGSN rs12663017 (B) and NOXRED1 rs8012548 (C) SNPs, Single 
nucleotide polymorphisms; MDACC, The University of Texas MD Anderson Cancer 
Center. 
Supporting information Figure 2.The combined risk genotypes and survival prediction. 
Kaplan-Meier survival curves of the combined risk genotypes in the MDACC dataset (A) 
and the NHS/HPFS dataset (C), and dichotomized groups of the NUG in the MDACC 
dataset (B), the NHS/HPFS dataset (D). NUG, number of unfavorable genotypes; 
MDACC, The University of Texas MD Anderson Cancer Center.  
 
 
Supporting information Table 1. List of 84 selected genes in the glutamine metabolic-related pathway genes 
Dataset Name  of pathway                       Number of genes 
GO CARBON NITROGEN LIGASE ACTIVITY WITH GLUTAMINE AS AMIDO N DONOR 12 
GO  GLUTAMINE FAMILY AMINO ACID BIOSYNTHETIC PROCESS  20  
GO GLUTAMINEFAMILYAMINOACIDCATABOLIC PROCESS 24 
GO GLUTAMINEFAMILYAMINOACIDMETABOLIC PROCESS 65  
GO GLUTAMINE FAMILY AMINO ACID METABOLIC PRIC PROCESS 14 









(after removing the 63 
duplicated genes) 
Keyword:  Glutamine 
Organism: Homo sapiens 
Website: http://software.broadinstitute.org/gsea/msigdb/search.jsp 
*(1) Pochini L, Scalise M, Galluccio M, Indiveri C. Membrane transporters for the special amino acid glutamine: structure/function relationships and relevance to human health. Front 
Chem 2014;2:61.  





   
Supporting information Table 2. Characteristics of the MDACC and Harvard NHS/HPFS studies  
Parameter 
  Frequency 
MFT HR (95% CI)1 P1   Patient Death (%) 
 MDACC  858 95 (11.1)  81.1   
 Age (years) ≤50 371 31 (8.4)  85.8 1.00  
 >50 487 64 (13.1)  78.1 1.69 (1.10-2.59) 0.017 
Sex Female 362 26 (7.2) 85.9 1.00  
 Male 496 69 (13.9) 77.8 2.07 (1.32-3.25) 0.002 
Regional/distantmetastasis No 709 51 (7.2) 82.7 1.00  
 Yes 149 44 (29.5) 69.4 4.78 (3.19-7.15) <0.001 
Breslow thickness (mm) ≤1 347 7 (2.0) 85.0 1.00  
 >1 511 88 (17.2) 78.1 9.17 (4.25-19.80) <0.001 
Ulceration No 681 48 (7.1) 84.0 1.00  
 Yes 155 43 (27.7) 64.3 4.91 (3.29-7.42) <0.001 
 Missing 22     
Mitotic rate (mm2) ≤1 275 9 (3.3) 82.2 1.00  
 >1 583 86 (14.8) 80.1 4.67 (2.35-9.29) <0.001 
 Harvard NHS/HPFS  409 48 (11.5)  179.0   
Age (years) ≤50 72 3 (4.2) 352.5 1.00  
 >50 337 45 (13.4)  167.0 4.04 (1.25–13.06) 0.020 
Sex Female 271 31 (11.4) 198.0 1.00  
  Male 138 17 (12.3)  155.5 1.16 (0.64-2.10) 0.622 
Abbreviations: MDACC, The University of Texas MD Anderson Cancer Center; NHS/HPFS: Nurses' Health Study/Health Professionals Follow-up Study; MFT, 
median follow-up time (months); HR, hazards ratio; CI, confidence interval; 




Supporting information Table 3. Comparison of multiple three testing correction methods (FPRP, BFDP 
and FDR). 
SNP P FPRP BFDP FDR 
rs17676826 0.010 0.081 0.570 0.9538 
rs1723518 0.022 0.165 0.292 0.9538 
rs9341780 0.022 0.165 0.292 0.9538 
rs1007519 0.024 0.179 0.212 0.9538 
rs1711934 0.024 0.179 0.253 0.9538 
rs12663017 0.024 0.179 0.738 0.9538 
rs8012548 0.021 0.169 0.713 0.9538 
Abbreviations: SNP, single nucleotide polymorphisms; FPRP, false-positive report probability; BFDP, 
Bayesian false discovery probability; FDR, false discovery rate.  
 
Supporting information Table 4. Function prediction of validated SNPs of genes in the glutamine metabolic pathway 


















rs17676826  HAL  12 95990567 4  ESC, IPSC, BLD IPSC 
 Zbtb3, GCNF, RXRA, 
Zfp691 1 hit 3 hits intronic 
rs1723518 LGSN  6 63274355 --     MZF1::1-4,NF-kappaB, ZBTB7A 
 1 hit  
rs9341780 LGSN  6 63274505 5     Myf  2 hits  
rs1007519 LGSN  6 63274970 5     CTCF,GR,Rad21,SMC3  1 hit  
rs1711934  LGSN  6 63275324 --     AP-2, BDP1, SETDB1, Znf143 
 1 hit  
rs12663017 LGSN  6 63275703 6  GI   
Foxa,Foxd1, Foxo-4, 
HDAC2, Hsf, Maf, TCF12, 
p300, 
 3 hits  
rs2253428# LGSN  6 63276569 --     HNF1,Mef2,TATA  1 hit 3'-UTR 
rs2253430# LGSN  6 63276607 --       1 hit 3'-UTR 
rs8012548  NOXRED1  14 77396520 6     Pitx2,Spz1  5 hits intronic 
rs10141317$ TMED8 14 77377010 4   49 tissues 
10 bound 
proteins BDP1,Sin3Ak-20, TCF12 
 3 hits missense 
rs3742737$ TMED8 14 77377041 2b 24 tissues   52 tissues 
12 bound 
proteins BHLHE40,CTCF,Smad4   5 hits missense 
Abbreviations: SNP, single nucleotide polymorphisms; Chr, chromosome; dbSNP func annot, dbSNP function annotation; Linkage disequilibrium, LD. 
1RegulomeDB (http://www.regulomedb.org) 
2HaploReg v4.1 (http://archive.broadinstitute.org/mammals/haploreg/haploreg.php) 
# Functional SNPs have high LD with LGSNrs12663017 (r2= 1). 






Supporting information Table 5. Stratified analysis of the risk genotypes of selected SNPs in MDACC and Harvard NHS/HPFS studies 
Characteristics  
0-1 risk genotypes1 2-3 risk genotypes1 Univariate analysis  Multivariate analysis2 
Phet3 Interaction4 
All Death (%) All Death (%) HR (95%CI) P HR (95%CI) P 
MDACC           
Age (years) 
         
≤ 50 185  13 (7.03)  186  18 (9.68)  1.47 (0.72-2.30)  0.292  2.06 (0.97-4.38)  0.059  
  
> 50 268  23 (8.58)  219  41 (18.72)  2.27 (1.36-3.79)  0.002 2.02 (1.18-3.45)  0.010  0.967  0.105 
Sex 
    
      
    Male  264  26 (9.85)  232  43 (18.53)  1.96 (1.21-3.20)  0.007 1.93 (1.15-3.23)  0.012   
    Female  189  10 (2.29)  173 16 (9.25) 1.85 (0.84-4.07) 0.128 2.42 (1.04-5.63) 0.040 0.654 0.229 
Regional/distant metastasis 
    No 368  15 (4.08)  341 36 (10.56) 2.63 (1.44-4.80)  0.002 2.11 (1.12-3.97)  0.021   
    Yes 85  21 (24.71)  64  23 (35.94)  1.70 (0.94-3.08)  0.079 1.78 (0.95-3.33)  0.071  0.708 0.521 
Breslow  thickness (mm) 
≤1 188  2 (1.06)  159  5 (3.14)  3.03 (0.59-15.63)  0.185  2.81 (0.42-18.81)  0.288    
>1 265  34 (12.83)  246  54 (21.95)  1.83 (1.19-2.81)  0.006  2.19 (1.36-3.31)  0.001   0.802  0.056 
Ulceration 
        
  
    No 363  20 (5.51)  318  28 (8.81)  1.61 (0.91-2.87)  0.102  1.56 (0.87-2.80)  0.135    
    Yes 79  15 (18.99)  76  28 (36.84)  2.26 (1.21-4.23)  0.011 2.60 (1.34-5.04)  0.005 0.257  0.735 
Missing 22          
Mitotic rate (mm2) 
≤1 154  3 (1.95)  121  6 (4.96)  2.67 (0.67-10.70)  0.165 5.64 (0.73-43.80)  0.098    
>1 299  33 (11.04)  284  53 (18.66)  1.75 (1.13-2.70)  0.012 1.93 (1.23-3.05)  0.005 0.316  0.541 
NHS/HPFS           
Age (years) 
         
 
≤ 50 42  2 (4.76)  30  1 (3.33)  0.71 (0.06-7.80)  0.777 0.67 (0.06-7.40)  0.740   
> 50 202  21 (10.40)  135  24 (17.78)  1.85 (1.03-3.33)  0.039  1.85 (1.03-3.33)  0.039  0.422  0.461 
Sex 
    
      
    Male  86  13 (15.12)  52  4 (7.69)  0.54 (0.17-1.64)  0.274  0.52 (0.17-1.61)  0.260    
    Female  158  10 (6.33)  113  21 (18.58)  3.16 (1.49-6.71)  0.003 3.03 (1.42-6.43)  0.004  0.011  0.010 
Abbreviations: SNP, single nucleotide polymorphisms; MDACC, The University of Texas MD Anderson Cancer Center; NHS/HPFS: Nurses' Health Study/Health Professionals Follow-up Study; 
HR, hazards ratio; CI, confidence interval; 
1Risk genotypes includedHAL rs17676826 TC+CC, LGSN rs12663017 TT and NOXRED1 rs8012548 AA; 
2Adjusted for age, sex, Breslow thickness, distant/regional metastasis, ulceration, and mitotic rate in Cox models of SNPs and CMSS in MDACC study and adjusted for age and sex in Harvard study; 
3Phet, heterogeneity test between subgroups. 
4Interaction: The interaction between the risk genotypes and each clinical variable. 
 
Reference 
1. Pochini L, Scalise M, Galluccio M, Indiveri C. Membrane transporters for the special amino acid glutamine: structure/function 
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